https://consumer.healthday.com/dupilumab-aids-survival-in-patients-hospitalized-for-covid-19-2657859503.html
0
0
35 words
0
Comments
No difference seen between dupilumab and placebo groups in adverse events or primary outcome of ventilator-free survival at 28 days
You are the first to view
Create an account or login to join the discussion